Equities research analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to report earnings of ($0.42) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.45) to ($0.40). Iovance Biotherapeutics posted earnings of ($0.27) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 55.6%. The firm is expected to issue its next quarterly earnings report on Wednesday, February 26th.

On average, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.50) per share for the current fiscal year, with EPS estimates ranging from ($1.53) to ($1.47). For the next financial year, analysts anticipate that the company will post earnings of ($1.70) per share, with EPS estimates ranging from ($2.32) to ($0.61). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.01).

Several research firms recently weighed in on IOVA. Chardan Capital reissued a “buy” rating and set a $33.00 price target on shares of Iovance Biotherapeutics in a report on Friday. Zacks Investment Research raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Thursday, October 17th. Stifel Nicolaus began coverage on Iovance Biotherapeutics in a report on Monday, September 30th. They set a “buy” rating and a $27.00 price target for the company. ValuEngine raised Iovance Biotherapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, B. Riley set a $28.00 price target on Iovance Biotherapeutics and gave the stock a “buy” rating in a report on Friday, August 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $29.27.

A number of institutional investors have recently bought and sold shares of the business. Coastal Investment Advisors Inc. increased its stake in Iovance Biotherapeutics by 2.9% during the 3rd quarter. Coastal Investment Advisors Inc. now owns 29,390 shares of the biotechnology company’s stock worth $534,000 after acquiring an additional 815 shares during the period. Strs Ohio increased its stake in Iovance Biotherapeutics by 0.7% during the 3rd quarter. Strs Ohio now owns 127,800 shares of the biotechnology company’s stock worth $2,325,000 after acquiring an additional 900 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in Iovance Biotherapeutics by 14.9% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,700 shares of the biotechnology company’s stock worth $189,000 after acquiring an additional 1,000 shares during the period. Tower Research Capital LLC TRC bought a new position in Iovance Biotherapeutics during the 2nd quarter worth $29,000. Finally, Edge Wealth Management LLC increased its stake in Iovance Biotherapeutics by 20.2% during the 2nd quarter. Edge Wealth Management LLC now owns 8,414 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 1,414 shares during the period. Hedge funds and other institutional investors own 97.24% of the company’s stock.

NASDAQ:IOVA traded down $0.97 during mid-day trading on Thursday, hitting $22.90. 1,359,500 shares of the stock were exchanged, compared to its average volume of 1,411,188. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of -18.03 and a beta of 1.96. The firm’s 50-day simple moving average is $19.93 and its 200 day simple moving average is $19.83. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.61 and a current ratio of 10.61. Iovance Biotherapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $26.59.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

See Also: Arbitrage

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.